Trials / Completed
CompletedNCT03911102
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DaxibotulinumtoxinA for injection | Intramuscular injection |
Timeline
- Start date
- 2019-03-11
- Primary completion
- 2020-04-23
- Completion
- 2020-04-23
- First posted
- 2019-04-10
- Last updated
- 2023-06-27
- Results posted
- 2023-06-27
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03911102. Inclusion in this directory is not an endorsement.